

13103696D

## SENATE BILL NO. 1285

Offered January 15, 2013

A BILL to amend and reenact §§ 54.1-3401 and 54.1-3457 of the Code of Virginia and to amend the Code of Virginia by adding a section numbered 54.1-3408.04, relating to dispensing of interchangeable biosimilar biological products.

Patron—Newman

Referred to Committee on Education and Health

**Be it enacted by the General Assembly of Virginia:**

**1. That §§ 54.1-3401 and 54.1-3457 of the Code of Virginia are amended and reenacted and that the Code of Virginia is amended by adding a section numbered 54.1-3408.04 as follows:**

**§ 54.1-3401. Definitions.**

As used in this chapter, unless the context requires a different meaning:

"Administer" means the direct application of a controlled substance, whether by injection, inhalation, ingestion, or any other means, to the body of a patient or research subject by (i) a practitioner or by his authorized agent and under his direction or (ii) the patient or research subject at the direction and in the presence of the practitioner.

"Advertisement" means all representations disseminated in any manner or by any means, other than by labeling, for the purpose of inducing, or which are likely to induce, directly or indirectly, the purchase of drugs or devices.

"Agent" means an authorized person who acts on behalf of or at the direction of a manufacturer, distributor, or dispenser. It does not include a common or contract carrier, public warehouseman, or employee of the carrier or warehouseman.

"Anabolic steroid" means any drug or hormonal substance, chemically and pharmacologically related to testosterone, other than estrogens, progestins, corticosteroids, and dehydroepiandrosterone.

"Animal" means any nonhuman animate being endowed with the power of voluntary action.

"Automated drug dispensing system" means a mechanical or electronic system that performs operations or activities, other than compounding or administration, relating to pharmacy services, including the storage, dispensing, or distribution of drugs and the collection, control, and maintenance of all transaction information, to provide security and accountability for such drugs.

"Biological product" means a virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, protein other than a chemically synthesized polypeptide, or analogous product, or arsphenamine or any derivative of arsphenamine or any other trivalent organic arsenic compound, applicable to the prevention, treatment, or cure of a disease or condition of human beings.

"Biosimilar" means a biological product that is highly similar to a specific reference biological product, notwithstanding minor differences in clinically inactive compounds, such that there are no clinically meaningful differences between the reference biological product and the biological product that has been licensed as a biosimilar pursuant to 42 U.S.C. § 262(k) in terms of the safety, purity, and potency of the product.

"Board" means the Board of Pharmacy.

"Bulk drug substance" means any substance that is represented for use, and that, when used in the compounding, manufacturing, processing, or packaging of a drug, becomes an active ingredient or a finished dosage form of the drug; however, "bulk drug substance" shall not include intermediates that are used in the synthesis of such substances.

"Change of ownership" of an existing entity permitted, registered, or licensed by the Board means (i) the sale or transfer of all or substantially all of the assets of the entity or of any corporation that owns or controls the entity; (ii) the creation of a partnership by a sole proprietor, the dissolution of a partnership, or change in partnership composition; (iii) the acquisition or disposal of 50 percent or more of the outstanding shares of voting stock of a corporation owning the entity or of the parent corporation of a wholly owned subsidiary owning the entity, except that this shall not apply to any corporation the voting stock of which is actively traded on any securities exchange or in any over-the-counter market; (iv) the merger of a corporation owning the entity or of the parent corporation of a wholly-owned subsidiary owning the entity with another business or corporation; or (v) the expiration or forfeiture of a corporation's charter.

"Compounding" means the combining of two or more ingredients to fabricate such ingredients into a single preparation and includes the mixing, assembling, packaging, or labeling of a drug or device (i) by

INTRODUCED

SB1285

59 a pharmacist, or within a permitted pharmacy, pursuant to a valid prescription issued for a medicinal or  
60 therapeutic purpose in the context of a bona fide practitioner-patient-pharmacist relationship, or in  
61 expectation of receiving a valid prescription based on observed prescribing patterns; (ii) by or for a  
62 practitioner of medicine, osteopathy, podiatry, dentistry, or veterinary medicine as an incident to his  
63 administering or dispensing, if authorized to dispense, a controlled substance in the course of his  
64 professional practice; or (iii) for the purpose of, or as incident to, research, teaching, or chemical  
65 analysis and not for sale or for dispensing. The mixing, diluting, or reconstituting of a manufacturer's  
66 product drugs for the purpose of administration to a patient, when performed by a practitioner of  
67 medicine or osteopathy licensed under Chapter 29 (§ 54.1-2900 et seq.) or a person supervised by such  
68 practitioner pursuant to subdivisions A 4, 6, or 19 of subsection A of § 54.1-2901, shall not  
69 be considered compounding.

70 "Controlled substance" means a drug, substance, or immediate precursor in Schedules I through VI of  
71 this chapter. The term shall not include distilled spirits, wine, malt beverages, or tobacco as those terms  
72 are defined or used in Title 3.2 or Title 4.1.

73 "DEA" means the Drug Enforcement Administration, ~~United States~~ U.S. Department of Justice, or its  
74 successor agency.

75 "Deliver" or "delivery" means the actual, constructive, or attempted transfer of any item regulated by  
76 this chapter, whether or not there exists an agency relationship.

77 "Device" means instruments, apparatus, and contrivances, including their components, parts, and  
78 accessories, intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in  
79 man or animals or to affect the structure or any function of the body of man or animals.

80 "Dialysis care technician" or "dialysis patient care technician" means an individual who is certified  
81 by an organization approved by the Board of Health Professions pursuant to Chapter 27.01 (§  
82 54.1-2729.1 et seq.) and who, under the supervision of a licensed physician, nurse practitioner, physician  
83 assistant, or a registered nurse, assists in the care of patients undergoing renal dialysis treatments in a  
84 Medicare-certified renal dialysis facility.

85 "Dialysis solution" means either the commercially available, unopened, sterile solutions whose  
86 purpose is to be instilled into the peritoneal cavity during the medical procedure known as peritoneal  
87 dialysis, or commercially available solutions whose purpose is to be used in the performance of  
88 hemodialysis not to include any solutions administered to the patient intravenously.

89 "Dispense" means to deliver a drug to an ultimate user or research subject by or pursuant to the  
90 lawful order of a practitioner, including the prescribing and administering, packaging, labeling, or  
91 compounding necessary to prepare the substance for that delivery. However, dispensing shall not include  
92 the transportation of drugs mixed, diluted, or reconstituted in accordance with this chapter to other sites  
93 operated by such practitioner or that practitioner's medical practice for the purpose of administration of  
94 such drugs to patients of the practitioner or that practitioner's medical practice at such other sites. For  
95 practitioners of medicine or osteopathy, "dispense" shall only include the provision of drugs by a  
96 practitioner to patients to take with them away from the practitioner's place of practice.

97 "Dispenser" means a practitioner who dispenses.

98 "Distribute" means to deliver other than by administering or dispensing a controlled substance.

99 "Distributor" means a person who distributes.

100 "Drug" means (i) articles or substances recognized in the official United States Pharmacopoeia  
101 National Formulary or official Homeopathic Pharmacopoeia of the United States, or any supplement to  
102 any of them; (ii) articles or substances intended for use in the diagnosis, cure, mitigation, treatment, or  
103 prevention of disease in man or animals; (iii) articles or substances, other than food, intended to affect  
104 the structure or any function of the body of man or animals; ~~or~~ (iv) articles or substances intended for  
105 use as a component of any article specified in clause (i), (ii), or (iii); *or (v) a biological product.* "Drug"  
106 does not include devices or their components, parts, or accessories.

107 "Drug product" means a specific drug in dosage form from a known source of manufacture, whether  
108 by brand or therapeutically equivalent drug product name.

109 "Electronic transmission prescription" means any prescription, other than an oral or written  
110 prescription or a prescription transmitted by facsimile machine, that is electronically transmitted directly  
111 to a pharmacy without interception or intervention from a third party from a practitioner authorized to  
112 prescribe or from one pharmacy to another pharmacy.

113 "Facsimile (FAX) prescription" means a written prescription or order, ~~which~~ *that* is transmitted by an  
114 electronic device over telephone lines that sends the exact image to the receiving pharmacy in hard copy  
115 form.

116 "FDA" means the ~~United States~~ U.S. Food and Drug Administration.

117 "Hashish oil" means any oily extract containing one or more cannabinoids, but shall not include any  
118 such extract with a tetrahydrocannabinol content of less than 12 percent by weight.

119 "Immediate precursor" means a substance which the Board of Pharmacy has found to be and by  
120 regulation designates as being the principal compound commonly used or produced primarily for use,

and which is an immediate chemical intermediary used or likely to be used in the manufacture of a controlled substance, the control of which is necessary to prevent, curtail, or limit manufacture.

*"Interchangeable" means a biosimilar that meets safety standards for determining interchangeability pursuant to 42 U.S.C. § 262(k)(4).*

"Label" means a display of written, printed, or graphic matter upon the immediate container of any article. A requirement made by or under authority of this chapter that any word, statement, or other information appear on the label shall not be considered to be complied with unless such word, statement, or other information also appears on the outside container or wrapper, if any, of the retail package of such article; or is easily legible through the outside container or wrapper.

"Labeling" means all labels and other written, printed, or graphic matter on an article or any of its containers or wrappers, or accompanying such article.

"Manufacture" means the production, preparation, propagation, conversion, or processing of any item regulated by this chapter, either directly or indirectly by extraction from substances of natural origin, or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis, and includes any packaging or repackaging of the substance or labeling or relabeling of its container. This term does not include compounding.

"Manufacturer" means every person who manufactures.

"Marijuana" means any part of a plant of the genus *Cannabis* whether growing or not, its seeds, or its resin; and every compound, manufacture, salt, derivative, mixture, or preparation of such plant, its seeds, or its resin. Marijuana shall not include any oily extract containing one or more cannabinoids unless such extract contains less than 12 percent of tetrahydrocannabinol by weight, nor shall marijuana include the mature stalks of such plant, fiber produced from such stalk, or oil or cake made from the seeds of such plant, unless such stalks, fiber, oil, or cake is combined with other parts of plants of the genus *Cannabis*.

"Medical equipment supplier" means any person, as defined in § 1-230, engaged in the delivery to the ultimate consumer, pursuant to the lawful order of a practitioner, of hypodermic syringes and needles, medicinal oxygen, Schedule VI controlled devices, those Schedule VI controlled substances with no medicinal properties ~~which~~ *that* are used for the operation and cleaning of medical equipment and solutions for peritoneal dialysis.

"Narcotic drug" means any of the following, whether produced directly or indirectly by extraction from substances of vegetable origin, or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis: (i) opium, opiates, and any salt, compound, derivative, or preparation of opium or opiates; (ii) any salt, compound, isomer, derivative, or preparation thereof which is chemically equivalent or identical with any of the substances referred to in clause (i), but not including the isoquinoline alkaloids of opium; (iii) opium poppy and poppy straw; (iv) coca leaves and any salt, compound, derivative, or preparation of coca leaves, and any salt, compound, isomer, derivative, or preparation thereof which is chemically equivalent or identical with any of these substances, but not including decocainized coca leaves or extraction of coca leaves which do not contain cocaine or ecgonine.

"New drug" means: (i) any drug, except a new animal drug or an animal feed bearing or containing a new animal drug, the composition of which is such that such drug is not generally recognized, among experts qualified by scientific training and experience to evaluate the safety and effectiveness of drugs, as safe and effective for use under the conditions prescribed, recommended, or suggested in the labeling, except that such a drug not so recognized shall not be deemed to be a "new drug" if at any time prior to the enactment of this chapter it was subject to the Food and Drugs Act of June 30, 1906, as amended, and if at such time its labeling contained the same representations concerning the conditions of its use; or (ii) any drug, except a new animal drug or an animal feed bearing or containing a new animal drug, the composition of which is such that such drug, as a result of investigations to determine its safety and effectiveness for use under such conditions, has become so recognized, but which has not, otherwise than in such investigations, been used to a material extent or for a material time under such conditions.

"Nuclear medicine technologist" means an individual who holds a current certification with the American Registry of Radiological Technologists or the Nuclear Medicine Technology Certification Board.

"Official compendium" means the official United States Pharmacopoeia National Formulary, official Homeopathic Pharmacopoeia of the United States, or any supplement to any of them.

"Official written order" means an order written on a form provided for that purpose by the ~~United States~~ *U.S.* Drug Enforcement Administration, under any laws of the United States making provision therefor, if such order forms are authorized and required by federal law, and if no such order form is provided then on an official form provided for that purpose by the Board of Pharmacy.

"Opiate" means any substance having an addiction-forming or addiction-sustaining liability similar to

182 morphine or being capable of conversion into a drug having such addiction-forming or  
183 addiction-sustaining liability. It does not include, unless specifically designated as controlled under  
184 Article 4 (§ 54.1-3437 et seq.) ~~of this chapter~~, the dextrorotatory isomer of  
185 3-methoxy-n-methylmorphinan and its salts (dextromethorphan). It does include its racemic and  
186 levorotatory forms.

187 "Opium poppy" means the plant of the species *Papaver somniferum* L., except the seeds thereof.

188 "Original package" means the unbroken container or wrapping in which any drug or medicine is  
189 enclosed together with label and labeling, put up by or for the manufacturer, wholesaler, or distributor  
190 for use in the delivery or display of such article.

191 "Person" means both the plural and singular, as the case demands, and includes an individual,  
192 partnership, corporation, association, governmental agency, trust, or other institution or entity.

193 "Pharmacist-in-charge" means the person who, being licensed as a pharmacist, signs the application  
194 for a pharmacy permit and assumes full legal responsibility for the operation of the relevant pharmacy in  
195 a manner complying with the laws and regulations for the practice of pharmacy and the sale and  
196 dispensing of controlled substances; the "pharmacist-in-charge" shall personally supervise the pharmacy  
197 and the pharmacy's personnel as required by § 54.1-3432.

198 "Poppy straw" means all parts, except the seeds, of the opium poppy, after mowing.

199 "Practitioner" means a physician, dentist, licensed nurse practitioner pursuant to § 54.1-2957.01,  
200 licensed physician assistant pursuant to § 54.1-2952.1, pharmacist pursuant to § 54.1-3300, TPA-certified  
201 optometrist pursuant to Article 5 (§ 54.1-3222 et seq.) of Chapter 32, veterinarian, scientific investigator,  
202 or other person licensed, registered, or otherwise permitted to distribute, dispense, prescribe and  
203 administer, or conduct research with respect to, a controlled substance in the course of professional  
204 practice or research in the Commonwealth.

205 "Prescriber" means a practitioner who is authorized pursuant to §§ 54.1-3303 and 54.1-3408 to issue  
206 a prescription.

207 "Prescription" means an order for drugs, *biological products*, or medical supplies, written or signed  
208 or transmitted by word of mouth, telephone, telegraph, or other means of communication to a pharmacist  
209 by a duly licensed physician, dentist, veterinarian, or other practitioner, authorized by law to prescribe  
210 and administer such drugs or medical supplies.

211 "Prescription drug" means any drug required by federal law or regulation to be dispensed only  
212 pursuant to a prescription, including finished dosage forms and active ingredients subject to § 503 (b) of  
213 the Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 353 (b)).

214 "Production" or "produce" includes the manufacture, planting, cultivation, growing, or harvesting of a  
215 controlled substance or marijuana.

216 "Proprietary medicine" means a completely compounded nonprescription drug in its unbroken,  
217 original package which does not contain any controlled substance or marijuana as defined in this chapter  
218 and is not in itself poisonous, and which is sold, offered, promoted, or advertised directly to the general  
219 public by or under the authority of the manufacturer or primary distributor, under a trademark, trade  
220 name, or other trade symbol privately owned, and the labeling of which conforms to the requirements of  
221 this chapter and applicable federal law. However, this definition shall not include a drug ~~which~~ *that* is  
222 only advertised or promoted professionally to licensed practitioners, a narcotic or drug containing a  
223 narcotic, a drug ~~which~~ *that* may be dispensed only upon prescription or the label of which bears  
224 substantially the statement "Warning - may be habit-forming," or a drug intended for injection.

225 "Radiopharmaceutical" means any drug that exhibits spontaneous disintegration of unstable nuclei  
226 with the emission of nuclear particles or photons and includes any non-radioactive reagent kit or  
227 radionuclide generator that is intended to be used in the preparation of any such substance, but does not  
228 include drugs such as carbon-containing compounds or potassium-containing salts that include trace  
229 quantities of naturally occurring radionuclides. The term also includes any biological product that is  
230 labeled with a radionuclide or intended solely to be labeled with a radionuclide.

231 "*Reference biological product*" means the single biological product licensed pursuant to 42 U.S.C.  
232 § 262(a) against which a biological product is evaluated in an application submitted to the U.S. Food  
233 and Drug Administration for licensure of biological products as biosimilar or interchangeable pursuant  
234 to 42 U.S.C. § 262(k).

235 "Sale" includes barter, exchange, or gift, or offer therefor, and each such transaction made by any  
236 person, whether as an individual, proprietor, agent, servant, or employee.

237 "Therapeutically equivalent drug products" means drug products that contain the same active  
238 ingredients and are identical in strength or concentration, dosage form, and route of administration and  
239 that are classified as being therapeutically equivalent by the ~~United States~~ U.S. Food and Drug  
240 Administration pursuant to the definition of "therapeutically equivalent drug products" set forth in the  
241 most recent edition of the Approved Drug Products with Therapeutic Equivalence Evaluations, otherwise  
242 known as the "Orange Book."

243 "USP-NF" means the current edition of the United States Pharmacopeia-National Formulary.

"Warehouser" means any person, other than a wholesale distributor, engaged in the business of selling or otherwise distributing prescription drugs or devices to any person who is not the ultimate user or consumer. No person shall be subject to any state or local tax by reason of this definition.

"Wholesale distribution" means distribution of prescription drugs to persons other than consumers or patients, subject to the exceptions set forth in § 54.1-3401.1.

"Wholesale distributor" means any person engaged in wholesale distribution of prescription drugs including, but not limited to, manufacturers; repackers; own-label distributors; private-label distributors; jobbers; brokers; warehouses, including manufacturers' and distributors' warehouses, chain drug warehouses conducting wholesale distributions, and wholesale drug warehouses; independent wholesale drug traders; and retail pharmacies conducting wholesale distributions. No person shall be subject to any state or local tax as a wholesale merchant by reason of this definition.

The words "drugs" and "devices" as used in Chapter 33 (§ 54.1-3300 et seq.) and in this chapter shall not include surgical or dental instruments, physical therapy equipment, X-ray apparatus, or glasses or lenses for the eyes.

The terms "pharmacist," "pharmacy," and "practice of pharmacy" as used in this chapter shall be defined as provided in Chapter 33 (§ 54.1-3300 et seq.) unless the context requires a different meaning.

**§ 54.1-3408.04. Dispensing of interchangeable biosimilars permitted.**

A. A biosimilar product determined to be interchangeable by the U.S. Food and Drug Administration shall be available for substitution in the Commonwealth.

B. A pharmacist may dispense a biosimilar that has been licensed by the U.S. Food and Drug Administration as interchangeable with the prescribed product unless (i) the prescriber indicates such substitute is not authorized by specifying on the prescription "brand medically necessary" or (ii) the patient insists on the dispensing of the prescribed biological product. In the case of an oral prescription, the prescriber's oral dispensing instructions regarding dispensing of an interchangeable biosimilar shall be followed. No pharmacist shall dispense a biosimilar in place of a prescribed biological product unless the biosimilar has been licensed as interchangeable with the prescribed biological product by the U.S. Food and Drug Administration for the specific use.

C. When a pharmacist dispenses an interchangeable biosimilar in the place of a prescribed biological product, the pharmacist or his designee shall inform the patient prior to dispensing the interchangeable biosimilar and shall indicate, unless otherwise directed by the prescriber, on both the record of dispensing and the prescription label, the brand name or, in the case of an interchangeable biosimilar, the product name and the name of the manufacturer or distributor of the interchangeable biosimilar. Whenever a pharmacist substitutes an interchangeable biosimilar pursuant to a prescription written for a brand-name product, the pharmacist or his designee shall label the drug with the name of the interchangeable biosimilar followed by the words "Substituted for" and the name of the biological product for which the prescription was written.

D. No restriction, limitation, or requirement shall be imposed on the substitution of a biosimilar for a biological product, unless such restriction, limitation, or requirement also applies to the substitution of any other drug for a therapeutically equivalent drug.

**§ 54.1-3457. Prohibited acts.**

The following acts shall be prohibited:

1. The manufacture, sale, or delivery, holding, or offering for sale of any drug, device, or cosmetic that is adulterated or misbranded.

2. The adulteration or misbranding of any drug, device, or cosmetic.

3. The receipt in commerce of any drug, device, or cosmetic that is adulterated or misbranded, and the delivery or proffered delivery thereof for pay or otherwise.

4. The sale, delivery for sale, holding for sale, or offering for sale of any article in violation of § 54.1-3421.

5. The dissemination of any false advertisement.

6. The refusal to permit entry or inspection, or to permit the taking of a sample, or to permit access to or copying of any record.

7. The giving of a false guaranty or undertaking.

8. The removal or disposal of a detained article in violation of § 54.1-3459.

9. The alteration, mutilation, destruction, obliteration, or removal of the whole or any part of the labeling of, or the doing of any other act with respect to, a drug, device, or cosmetic, if such act is done while such article is held for sale and results in such article being adulterated or misbranded.

10. The forging, counterfeiting, simulating, or falsely representing, or without proper authority using of any mark, stamp, tag, label, or other identification device authorized or required by regulations promulgated under the provisions of this chapter or of the federal act.

11. The using by any person to his own advantage, or revealing, other than to the Board or its authorized representative or to the courts when relevant in any judicial proceeding under this chapter of

305 any information acquired under authority of this chapter concerning any method or process which as a  
306 trade secret is entitled to protection.

307 12. The using, on the labeling of any drug or in any advertisement relating to such drug, of any  
308 representation or suggestion that an application with respect to such drug is effective under § 54.1-3421,  
309 or that such drug complies with the provisions of such section.

310 13. In the case of a drug distributed or offered for sale in this Commonwealth, the failure of the  
311 manufacturer, packer, or distributor thereof to maintain for transmittal, or to transmit, to any practitioner  
312 licensed by applicable law to administer such drug who makes written request for information as to such  
313 drug, true and correct copies of all printed matter which is required to be included in any package in  
314 which that drug is distributed or sold, or such other printed matter as is approved under the federal act.  
315 This subdivision shall not be construed to exempt any person from any labeling requirement imposed by  
316 or under other provisions of this chapter.

317 14. Placing or causing to be placed upon any drug or device or container, with intent to defraud, the  
318 trade name or other identifying mark, or imprint of another or any likeness of any of the foregoing; or  
319 selling, dispensing, disposing of, or causing to be sold, dispensed, or disposed of, or concealing or  
320 keeping in possession, control, or custody, with intent to sell, dispense, or dispose of, any drug, device,  
321 or any container thereof, with knowledge that the trade name or other identifying mark or imprint of  
322 another or any likeness of any of the foregoing has been placed thereon in a manner prohibited by this  
323 section or making, selling, disposing of, or causing to be made, sold, or disposed of, or keeping in  
324 possession, control, or custody, or concealing any punch, die, plate, stone, or other thing designed to  
325 print, imprint, or reproduce the trademark, trade name, or other identifying mark, imprint, or device of  
326 another or any likeness of any of the foregoing upon any drug or container or labeling thereof so as to  
327 render such drug a counterfeit drug.

328 15. The doing of any act ~~which~~ *that* causes a drug to be a counterfeit drug, or the sale or dispensing,  
329 or the holding for sale or dispensing, of a counterfeit drug.

330 16. Dispensing or causing to be dispensed a different drug or brand of drug in place of the drug or  
331 brand of drug ordered or prescribed without the permission of the person ordering or prescribing, except  
332 as provided in § 54.1-3408.03 relating to dispensing of therapeutically equivalent drugs.

333 17. *Dispensing or causing to be dispensed a biosimilar in place of a prescribed biological product*  
334 *or brand of biological product, except as provided in § 54.1-3408.04 related to dispensing of*  
335 *interchangeable biosimilars.*